Back to Browse Journals » Drug Design, Development and Therapy » Volume 2

Development and targeted use of nilotinib in chronic myeloid leukemia

Authors Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Published Date November 2008 Volume 2008:2 Pages 233—243

DOI http://dx.doi.org/10.2147/DDDT.S3181

Published 10 November 2008

Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abstract: The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired resistance has been traced to Bcr-Abl kinase domain mutations. Several strategies have been developed to overcome the problem of imatinib resistance, including imatinib dose escalation, novel targeted agents and combination treatments. A second generation of tyrosine kinase inhibitors was developed, which displays increased potency towards Bcr-Abl and is able to target the majority of CML mutant clones. Nilotinib (Tasigna®, AMN107, Novartis) is a close analog of imatinib with approximately 20-fold higher potency for BCR-ABL kinase inhibition. Preclinical and clinical investigations demonstrate that nilotinib effectively overcomes imatinib resistance, and has induced high rates of hematologic and cytogenetic responses in CML post imatinib failure, with a good tolerance. Nilotinib has been approved for CML patients in chronic and accelerated phases, post imatinib failure.

Keywords: nilotinib, imatinib-resistance, imatinib-intolerance, CML

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Elias Jabbour, Jorge Cortes, Hagop Kantarjian

Core Evidence 2009, 4:207-213

Published Date: 5 October 2009

Readers of this article also read:

Evaluation of the Prevention and Reactivation Care Program (PReCaP) for the hospitalized elderly: a prospective nonrandomized controlled trial

Asmus-Szepesi KJ, Flinterman LE, Koopmanschap MA, Nieboer AP, Bakker TJ, Mackenbach JP, Steyerberg EW

Clinical Interventions in Aging 2015, 10:649-661

Published Date: 30 March 2015

Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study

Liang CL, Wang HK, Syu FK, Wang KW, Lu K, Liliang PC

Clinical Interventions in Aging 2015, 10:635-642

Published Date: 27 March 2015

Toward an online cognitive and emotional battery to predict treatment remission in depression

Gordon E, Rush AJ, Palmer DM, Braund TA, Rekshan W

Neuropsychiatric Disease and Treatment 2015, 11:517-531

Published Date: 26 February 2015

Corrigendum

Wu Q, Chu M

International Journal of Nanomedicine 2012, 7:4531-4532

Published Date: 15 August 2012

Corrigendum

Brief G, Lammich T, Nagel E, Pfennigsdorf S, Spraul CW, Ho S

Clinical Ophthalmology 2012, 6:1271-1272

Published Date: 6 August 2012

Corrigendum

Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision

Espandar L, Sikder S, Moshirfar M

Clinical Ophthalmology 2011, 5:159-160

Published Date: 6 February 2011